Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 2/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 10/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.43 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.43 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4396809 | 0.93 | OPRM1 (0.47) | OPRM1OPRD1OPRK1GLP1RECE1 | |
| SCHEMBL4396699 | 0.92 | OPRM1 (0.51) | OPRM1OPRD1OPRK1GLP1RECE1 | |
| SCHEMBL13724097 | 0.91 | PSEN1 (0.51) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL4092686 | 0.89 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13724103 | 0.87 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13722966 | 0.87 | PSEN1 (0.49) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL16358277 | 0.87 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12293279 | 0.87 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13323741 | 0.87 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13724091 | 0.87 | PSEN1 (0.43) | GLP1RPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105119-A1 | ASPARAGINE-10-SUBSTITUTED NONADEPSIPEPTIDES | BAYER SCHERING PHARMA AG (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105119-A1 | ASPARAGINE-10-SUBSTITUTED NONADEPSIPEPTIDES | ASNS, DNPEP, ANPEP | OPRM1 3788/4885OPRD1 3240/4885OPRK1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.